Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables (2016 - 2025)

China Pharma Holdings filings provide 16 years of Change in Receivables readings, the most recent being -$13.5 million for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 6444.99% to -$13.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.2 million, a 6780.77% decrease, with the full-year FY2025 number at -$13.2 million, down 6780.77% from a year prior.
  • Change in Receivables hit -$13.5 million in Q4 2025 for China Pharma Holdings, down from $117491.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $434306.0 in Q1 2023 to a low of -$13.5 million in Q4 2025.
  • Median Change in Receivables over the past 5 years was $113758.0 (2022), compared with a mean of -$567847.9.
  • Biggest five-year swings in Change in Receivables: skyrocketed 578.17% in 2022 and later tumbled 6444.99% in 2025.
  • China Pharma Holdings' Change in Receivables stood at $393662.0 in 2021, then plummeted by 72.75% to $107286.0 in 2022, then soared by 239.52% to $364258.0 in 2023, then tumbled by 41.54% to $212942.0 in 2024, then tumbled by 6444.99% to -$13.5 million in 2025.
  • The last three reported values for Change in Receivables were -$13.5 million (Q4 2025), $117491.0 (Q3 2025), and $20566.0 (Q2 2025) per Business Quant data.